Betwwen the Lines Interesting to note that ALNY in the release on the 19th that they are going into a restructuring to generate a larger cash reserve and laying off a large number of of employees to save an estimated 20 million per anum.
Also the comment in the cautionary statements section that mentions the potential of a not so goode outcome for them in ongoing litigation.
Standard cover your butt wording for a discretionary statement although it may be telling of their worries about TKM claim of damages. Read it and make your own judgement.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Alnylam Forward-Looking Statements
Various statements in this release concerning Alnylam's future expectations, plans and prospects, including, without limitation, Alnylam's planned strategic corporate restructuring, including the timing and effect of the restructuring on Alnylam's future operating expenses and cash position, and the timing and amount of one-time charges related to the personnel reductions expected to be incurred, its plans for the continued research and development of RNAi therapeutics, its expected cash position as of December 31, 2011, its expectations regarding issuing financial guidance for 2012 and statements regarding Alnylam's expectations with respect to its "Alnylam 5x15" product strategy, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, risks and uncertainties related to Alnylam's ability to successfully implement its strategic corporate restructuring and workforce reduction plan and achieve the estimated cost savings; the impact of the workforce reduction on Alnylam's business, the ability of Alnylam to attract and retain qualified personnel, Alnylam's ability to manage operating expenses, Alnylam's ability to discover and develop novel drug candidates and delivery approaches, successfully demonstrate the efficacy and safety of its drug candidates, the pre-clinical and clinical results for its product candidates, which may not support further development of product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, obtaining, maintaining and protecting intellectual property, Alnylam's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, obtaining regulatory approval for products, competition from others using technology similar to Alnylam's and others developing products for similar uses, Alnylam's ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, Alnylam's dependence on third parties for development, manufacture, marketing, sales and distribution of products, the outcome of litigation, unexpected expenditures and Alnylam's short operating history, as well as those risks more fully discussed in the "Risk Factors" section of its most recent quarterly report on Form 10-Q on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam does not assume any obligation to update any forward-looking statements.
SOURCE: Alnylam Pharmaceuticals, Inc.